Higher plasma phosphorylated tau 217 levels are associated with a greater risk of cognitive impairment, with apolipoprotein E ε4 carrier status helping researchers estimate both risk and timing. A pooled analysis of prospective cohort studies published in The Lancet Neurology examines data spanning 1992 to 2025 across multiple multiethnic groups.
Blood-based biomarkers of Alzheimer’s disease pathology are reshaping how researchers evaluate neurological risk. Among these markers, plasma phosphorylated tau 217 concentrations have emerged as an effective tool for identifying neuropathological changes before overt symptoms appear.
While the biomarker signals underlying biological changes, people with equivalent p-tau217 levels can follow different clinical trajectories. A pooled analysis published in The Lancet Neurology investigates whether genetic background accounts for this variation.
Pooled Analysis Across Seven Prospective Cohorts
To evaluate the influence of p-tau217 and the apolipoprotein E (APOE) genotype on cognitive impairment, researchers analyzed participant-level data from seven multiethnic prospective cohort studies of older adults. The investigation drew from community-based settings and academic research centers across the United States, Canada, and the Dominican Republic.
The analyzed cohorts include the Alzheimer’s Disease Neuroimaging Initiative (ADNI), the Health & Aging Brain Study-Health Disparities (HABS-HD), and the Estudio Familiar de Influencia Genética en Alzheimer (EFIGA). Additional data came from the Washington Heights, Hamilton Heights, Inwood Columbia Aging Project (WHICAP), the Religious Orders Study/Rush Memory and Aging Project (ROSMAP), the Wisconsin Registry for Alzheimer’s Prevention (WRAP), and the Wisconsin Alzheimer’s Disease Research Center (Wisconsin-ADRC).
The study sample comprised 8,582 individuals with a mean age of 70 years, consisting of 66% female and 34% male participants. Non-Hispanic Whites accounted for 47% of the cohort, Black participants represented approximately 16%, and Hispanic individuals or those from other ethnic groups made up the remaining 37%. The longitudinal analyses focused on 4,569 participants who showed no cognitive impairment at the start of the study and completed at least one follow-up clinical assessment.
APOE Genotype and the Timing of Cognitive Decline
The analysis revealed that higher baseline p-tau217 concentrations correlated with increased odds of cognitive impairment at baseline and a greater likelihood of future decline. Crucially, the association was stronger among participants carrying the APOE-ε4 allele compared to non-carriers.
In addition to risk estimation, APOE-ε4 carrier status provided additional prognostic information regarding how quickly impairment emerged. Each standard deviation increase in plasma p-tau217 levels corresponded to a 24% shorter time to cognitive impairment among APOE-ε4 carriers, compared to a 13% shorter time among non-carriers.
Complementary findings presented at the Alzheimer’s Association International Conference provided further granularity on risk timeframes. Rachel F. Buckley and Reisa A.
“This study was motivated by the question: what does plasma p-tau217 tell us about a cognitively unimpaired older adult’s future risk of developing cognitive impairment?”
Rachel F. Buckley, PhD, and Reisa A. Sperling, MD, Harvard Medical School, via Healio
Data derived from research presented in London showed that among 2,705 cognitively unimpaired older adults, risks for cognitive impairment increased by 38% with each standard deviation increase in p-tau217. Individuals with very high baseline levels faced a 78% likelihood of developing cognitive impairment within a decade.
Implications for Clinical Care and Secondary Prevention Trials
The ability to stratify risk using accessible blood-based markers addresses significant barriers in neurological care. Traditional diagnostic methods like cerebrospinal fluid analysis and positron emission tomography scans remain invasive, expensive, and resource-intensive.
Researchers emphasized that blood-based markers allow for wider access to biomarker research and clinical care at a fraction of the cost. Buckley and Sperling highlighted the timeliness of these models as secondary prevention trials advance.
“This is especially timely because we may soon see successful secondary prevention trials in cognitively unimpaired individuals with Alzheimer’s disease pathology. If preventive treatments become available, we will need robust, interpretable prediction models that incorporate blood-based biomarkers like p-tau217.”
Rachel F. Buckley, PhD, and Reisa A. Sperling, MD, Harvard Medical School, via Healio
By combining peripheral biomarker concentrations with genetic factors such as the APOE genotype, clinicians move closer to individualized risk estimates. This approach replaces generalized population-level relative risks with interpretable prognostic data, helping identify patients who may benefit from closer monitoring as preventive options develop.
